Business Wire

New Calabrio Report, Launched at Customer Event, Diagnoses Why Contact Centers Struggle with High Agent Turnover in 2021

5.10.2021 17:15:00 EEST | Business Wire | Press release

Share

Calabrio, the customer experience intelligence company, today unveiled its latest report, detailing first-hand agent sentiment on the current state of the contact center, the impact that “The Great Resignation” has had on contact centers and the importance of employee-centric practices. The findings were announced on the first day of the annual Calabrio Customer Connect (C3) conference. This year Calabrio’s annual conference, focused on The Connected Workforce, is being held as a virtual event October 5-6, 2021.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005005256/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Data from Calabrio's agent wellbeing survey uncovers transformational opportunities for the contact center and shows the key importance of employee-centricity. (Photo: Business Wire)

As “The Great Resignation” sweeps across the global labor landscape, many businesses are left both shorthanded and questioning what they could have done to keep their workforce. The study, entitled “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation,” surveyed U.S. and UK contact center agents to uncover transformational opportunities for the contact center from their perspective. Calabrio previously surveyed agents on the same topic in 2017. Whereas the 2017 study was completed before the accelerated shift to remote work, 65% of this study’s respondents were speaking from experience in a hybrid or remote role. This year’s findings reveal that contact centers must prioritize agent retention and engagement or face a dangerous cycle of attrition.

The report found that contact center agents suffer tremendous stress from modern workforce challenges, including rising customer expectations, growing call volume and a shaky work-life balance. According to the study, one-third of agents report feeling acutely stressed multiple times per week. This is an increase from 2017, when just 25% of agents reported that feeling.

Even more importantly, most agents also report that their companies are not doing enough to address agent stress. This agent sentiment has created a never-ending cycle of stress and disengagement, where a third of agents are considering leaving their jobs within one year, and half plan to leave within two or three years.

“Agents are a brand’s only defenders and key ambassadors during this pandemic, and they continue to face one of the most difficult customer service eras in recent memory. Staffing levels are often low while customer expectations are high. Understanding the agent experience is the first step in providing the support they need. This report illustrates that now is the time for contact centers to prioritize the creation of a targeted agent-engagement and retention plan,” said Tom Goodmanson, president and CEO at Calabrio. “As C3 begins, we are excited to share our findings and work together with industry peers and leaders to improve the agent experience, including pushing for a more connected workforce, increased agent flexibility and a greater investment in agent-empowering technologies.”

Other takeaways from the study that tie into the C3 theme of The Connected Workforce include:

  • Money Isn’t Everything: The report found that there is a disconnect between the most asked-for items from agents and their top reasons for leaving. For example, the top ask from agents is more pay, however the top reason for leaving is being unhappy in the job. More money is the number three reason for leaving.
  • Flexibility Isn’t Just About Location: While most agents report that they are now working in their preferred environment, more flexibility is still the second most common agent request.
  • Technology Investments Are Working, But We’re Not There Yet: More agents in this year’s study feel they have the correct technology to handle challenges compared to the 2017 study, but “lack of tools” and “lack of data” are still the top two reasons agents report for why they fail to solve customer issues.

For a full report of the data and findings go to “Health of the Contact Center 2021: Agent Wellbeing and the Great Resignation.”

About Calabrio Customer Connect: October 5-6, 2021

Attend Calabrio Customer Connect (C3) to learn more about the importance of employee-centric practices and to hear from contact center peers on specific ideas for retaining staff. The annual event brings together the global contact center industry for education and networking and features more than 50 breakout sessions and keynotes from industry leaders. This year, the virtual event will feature multiple tracks to accommodate different attendees, such as the Workforce Connection, Performance Connection, Complete Connection, Partner Connection and the Connected Enterprise. To register and view this year’s breakout sessions, visit: https://www.calabriocustomerconnect.com/breakout-sessions/.

About Calabrio

Calabrio is the customer experience intelligence company that empowers organizations to enrich human interactions. The scalability of our cloud platform allows for quick deployment of remote work models—and it gives our customers precise control over both operating costs and customer satisfaction levels. Our AI-driven analytics tools make it easy for contact centers to uncover customer sentiment and share compelling insights with other parts of the organization. Customers choose Calabrio because we understand their needs and provide a best-in-class experience, from implementation to ongoing support. Find more at calabrio.com and follow @Calabrio on Twitter.

Calabrio, Calabrio ONE® and the Calabrio logo are registered trademarks or trademarks of Calabrio, Inc. All other trademarks mentioned in this document are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Amy Fisher
612.455.1773
CalabrioPR@padillaco.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye